Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

Mirtazapine and Methamphetamine Drug-drug Interaction Study

A legfontosabb adatok

Ki végzi
San Francisco Department of Public Health
Hol
Los Angeles és San Francisco (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
15 fő vett részt
Kezdés
2021. máj. 3.
Befejezés
2024. máj. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Mirtazapine
  • Methamphetamine
A regiszteradat frissítve
2024. szeptember 27.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • English-speaking
  • age 18-55 years inclusive
  • meet DSM-V criteria for MA use disorder, as diagnosed via SCID
  • provide MA-positive urine during screening
  • have a resting heart rate of 50-90
  • have a systolic blood pressure ≤ of 100-150 mm Hg, and diastolic blood pressure of 45-90 Hg within two days prior to admission
  • have a baseline EKG that demonstrates normal sinus rhythm, QTc < 440 msec in men or QTc < 450 msec in women
  • have acceptable safety lab data, ALT / AST<3x upper limit nL; est GFR >50
  • if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 7 days after the last dose of study medication
  • For those who also use opioids and are on methadone maintenance treatment (Group 2), urine positive for methadone and negative for buprenorphine on admission

Ki nem vehet részt

  • current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics)
  • urine positive for MA and other unplanned drugs on the day of admission and breathalyzer results negative for alcohol
  • any prior adverse reaction to MA; including chest pain or epileptic seizure
  • Have current cocaine, cannabis, or alcohol use disorder by DSM-V SCID
  • current or past history of seizure disorder
  • major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the SCID
  • have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent
  • history of suicide attempt(s) in the past 90 days or current suicidal intent or plan by SCID
  • evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection
  • any serious medical or psychiatric AE after test infusion of MA 30mg IV (e.g. sustained SBP>200 or DBP>100; sustained pulse >(220-0.85xAge)
  • seeking treatment for MA problems at the time of the study
  • any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial

Helyszínek itt: Egyesült Államok

  • UCLA Medical CenterLos Angeles, Egyesült Államok
  • San Francisco Department of Public HealthSan Francisco, Egyesült Államok
  • Substance Use Research UnitSan Francisco, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA.

A teljes eredeti leírásKevesebb

Aim 1: To determine if mirtazapine alters the cardiovascular response to IV MA.

Aim 2: To determine if the pharmacokinetics of IV MA are altered by mirtazapine administration.

Aim 3: To evaluate the above aims in the setting of concomitant administration of methadone.

This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have methamphetamine use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine).

A vizsgálat 2 csoportja

  • MirtazapineA vizsgált kezelés

    Mirtazapine 30 mg PO daily x 4 days

    Kezelés: Mirtazapine és Methamphetamine

  • PlaceboPlacebo, összehasonlításként

    Placebo 30 mg PO Daily x 4 days

    Kezelés: Methamphetamine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
A regiszteradat frissítve
2024. szeptember 27.